Even Benchmark thinks AI is eroding the venture pact against backing rivals
THE SO WHAT
If even Benchmark is questioning the old norm against backing direct rivals, AI’s pace and horizontal reach are forcing VCs to optimize for exposure, not exclusivity. Founders should assume their investors may back competitors and design moats around data, distribution, and integration depth — not cap table loyalty.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureThe 'blurry' world of defence tech revenue
Defence tech ARR is structurally lumpy—multi-year pilots, milestone-based contracts, and classified budgets make SaaS-style metrics almost meaningless. If you're building or backing in this space, underwrite to program wins and procurement cycles, not logo counts and MRR charts.
Startups & Venture‘I’m 30. I’ve got one more shot’: Reson8’s founder wants to build a European AI giant
The more founders talk about building a 'European AI giant,' the clearer the gap between ambition and regional scale dynamics becomes—talent, capital, and compute are still concentrated elsewhere. If you're operating in Europe, assume cross-border expansion and US/Asia partnerships are part of the plan from day one, not a later stage.
Startups & VentureAustin-based RapidCanvas, which uses agents to help businesses build custom AI tools, raised a ∼$29M Series B led by Vertex Ventures and Hitachi Ventures
A $29M Series B for RapidCanvas is more fuel behind 'AI to build AI'—agentic platforms that promise line-of-business teams custom apps without full-stack ML teams. If you're an enterprise CIO, you now have to decide whether to standardize on one of these meta-builders or double down on internal platform teams before shadow AI proliferates.
Startups & VentureCity Therapeutics Raises $200 Million in Upsized US IPO
Early-stage RNAi can still clear public markets at the midpoint of the range—biotech IPOs are reopening for platforms with a crisp story even before late-stage data. If you’re building in therapeutics, the window is shifting from binary ‘open/closed’ to selective access for modality narratives investors understand.